

Turkey

Population 2015

79 million

| Estimates of TB burden*, 2015 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|---------------------|-------------------------------|
| Mortality (excludes HIV+TB) | 0.74 (0.63–0.85) | 0.94 (0.8–1.1) |
| Mortality (HIV+TB only) | 0.015 (<0.01–0.044) | 0.02 (0–0.06) |
| Incidence (includes HIV+TB) | 14 (12–17) | 18 (16–21) |
| Incidence (HIV+TB only) | 0.097 (0.082–0.11) | 0.12 (0.1–0.15) |
| Incidence (MDR/RR-TB)** | 0.71 (0.6–0.83) | 0.9 (0.76–1.1) |

Estimated TB incidence by age and sex (thousands)*, 2015

| | 0-14 years | > 14 years | Total |
|---------|-----------------|---------------|---------------|
| Females | 0.64 (0.38–0.9) | 5.7 (4.3–7.2) | 6.4 (4.7–8.1) |
| Males | 0.6 (0.41–0.8) | 7.5 (5.8–9.1) | 8.1 (6.2–9.9) |
| Total | 1.2 (0.92–1.6) | 13 (12–14) | 14 (12–17) |

TB case notifications, 2015

| | |
|--|--------|
| Total cases notified | 12 772 |
| Total new and relapse | 12 550 |
| - % tested with rapid diagnostics at time of diagnosis | |
| - % with known HIV status | 70% |
| - % pulmonary | 64% |
| - % bacteriologically confirmed among pulmonary | 77% |

Universal health coverage and social protection

| | |
|--|------------------|
| TB treatment coverage (notified/estimated incidence), 2015 | 87% (75–100) |
| TB patients facing catastrophic total costs | |
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 | 0.05 (0.04–0.06) |

TB/HIV care in new and relapse TB patients, 2015

| | Number | (%) |
|---|--------|-----|
| Patients with known HIV-status who are HIV-positive | 59 | <1% |
| - on antiretroviral therapy | 54 | 92% |

| Drug-resistant TB care, 2015 | New cases | Previously treated cases | Total number*** |
|---|----------------|---------------------------|-----------------|
| Estimated MDR/RR-TB cases among notified pulmonary TB cases | | | 440 (390–490) |
| Estimated % of TB cases with MDR/RR-TB | 3.6% (3.1–4.2) | 21% (17–24) | |
| % notified tested for rifampicin resistance | 43% | 60% | 5 648 |
| MDR/RR-TB cases tested for resistance to second-line drugs | | | 136 |
| Laboratory-confirmed cases | | MDR/RR-TB: 304, XDR-TB: 3 | |
| Patients started on treatment **** | | MDR/RR-TB: 238, XDR-TB: 3 | |

| Treatment success rate and cohort size | Success | Cohort |
|---|---------|--------|
| New and relapse cases registered in 2014 | 87% | 12 933 |
| Previously treated cases, excluding relapse, registered in 2014 | 50% | 192 |
| HIV-positive TB cases, all types, registered in 2014 | 66% | 41 |
| MDR/RR-TB cases started on second-line treatment in 2013 | 65% | 228 |
| XDR-TB cases started on second-line treatment in 2013 | 33% | 3 |

TB preventive treatment, 2015

| | |
|---|----------------|
| % of HIV-positive people (newly enrolled in care) on preventive treatment | |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment | 100% (100–100) |

TB financing, 2016

National TB budget (US\$ millions)

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

